Hepatitis B Management Guidelines

Introduction to Hepatitis B Management

The European Association for the Study of the Liver (EASL) recommends that patients with decompensated cirrhosis should receive nucleos(t)ide analogues (NAs) as early as possible, with entecavir or tenofovir being the preferred treatment options for patients with decompensated disease 1
For patients with HBV reactivation causing acute-on-chronic liver failure, nucleoside analogues (tenofovir, entecavir) should be instituted as early as possible, according to the EASL guidelines 2

The European Society for Clinical Nutrition and Metabolism (ESPEN) guidelines recommend an energy intake of 35-40 kcal/kg body weight/day and a protein intake of 1.2-1.5 g/kg body weight/day for patients with chronic liver disease 3
Oral nutritional supplements should be used when patients cannot meet caloric requirements through normal food, and branched-chain amino acid (BCAA)-enriched formulas should be used in patients who develop hepatic encephalopathy during enteral nutrition, as per the ESPEN guidelines 3

Regular monitoring of liver function tests (ALT, AST, bilirubin), HBV DNA levels to assess viral suppression in treated patients, alpha-fetoprotein, and ultrasound for hepatocellular carcinoma surveillance in eligible patients is recommended 4
Vitamin D levels should be checked after 3 months of supplementation, with a target level above 30 ng/mL (75 nmol/L) 4

The American College of Hepatology and other guideline societies recommend avoiding unregulated herbal supplements, as many have not been adequately tested and may cause hepatotoxicity 5
Any supplement use should be discussed with healthcare providers to avoid potential drug interactions, and the focus should be on evidence-based treatments, with antiviral therapy being the cornerstone of hepatitis B management for eligible patients 1, 5

For patients with decompensated cirrhosis, management should be coordinated with transplant centers, according to the American Association for the Study of Liver Diseases (AASLD) and other guideline societies 5
Patients with acute-on-chronic liver failure may require intensive care support in addition to antiviral therapy, as recommended by the EASL guidelines 2